THERAPEUTIC VACCINES MARKET ANALYSIS

Vaccine is a biological product that initiates stimulation to antibodies and helps provide immunity against infectious and chronic diseases. There are various types of vaccines such as inactivated vaccines, subunit vaccines, recombinant vector vaccines and DNA vaccines. Vaccines are mainly prophylactic in nature along with therapeutic effect. The wide application of vaccines is expected to favor the therapeutic vaccines market. Therapeutic vaccine is a combination of biologics that is designed to develop immunity against the abnormal cells in the body. Therapeutic vaccines can be modified as per application and can be used to treat various disorders and disease such various types of cancer, HIV infectious diseases, and Alzheimer’s disease. Therapeutic vaccines help treat a disorder by inducing or providing strength to the immune response. However, the existence of a handful of established therapeutic vaccines and their explored property has provided a resistance in the therapeutic vaccine market growth till now. Although, various studies and demand for biologics has provided a significant shift of growth graph towards high value.

Therapeutic vaccines are particularly designed to treat patients who have tested HIV positive. HIV virus deteriorates the immune system that results in weakening of its response towards the disease and abnormality causing agents resulting in inability to fight with those agents. According to, U.S. Department of Health and Human Services, in 2010, there were various vaccines under phase 3 clinical trials, such as gp100 melanoma vaccine, Lucanix (Belagenpumatucel-L) (NovaRx Corp.) for NSCLC, GSK1572932A (GSK) for melanoma and NSCLC, and Stimuvax (Emepepimut-S) (Merck KGaA/Oncothyreon). 

Therapeutic Vaccines Market Taxonomy:

By Vaccines Type

• Auto Immune Diseases Vaccines
• Neurological Disease Vaccines
• Cancer Vaccines
• Infectious Diseases Vaccines

By Indication

• Cancer
• Breast Cancer
• Prostate Cancer
• Lung cancer
• Melanoma
• others
• Infectious Disease
• HIV
• Hepatitis B
• Hepatitis C
• Others
• Other Chronic Diseases
• Alzheimer’s
• Allergy
• Others

Rising demand for biologics and drugs for specific treatment is expected to favor growth of the therapeutic vaccines market in the near future

The global therapeutic vaccines market is significantly affected by increasing prevalence of cancer, HIV infection, cardiovascular diseases, and various chronic diseases. This exponential growth in prevalence of such diseases is expected to increase the demand for biologic drugs for specific or targeted response, which is further projected to support increase in growth of therapeutic vaccines industry in the near future. According to AVERT, a global organization involved in providing information and education on HIV and AIDS to the general population, in 2016, around 37 million people worldwide were infected by HIV and 40% were unaware about it. According to a report by America’s Biopharmaceutical Research Companies, in 2013, around 300 vaccines were in development, with research focused on prevention and treatment. These vaccines include treatment of various health issues and diseases such as allergy, cancer, infectious disease, and neurological disorder. Furthermore, according to data from the U.S. Centers for Disease Control and Prevention (CDC), therapeutic vaccines have led to the eradication of around 10 infectious diseases by up to 90% in the U.S.

Major players in the therapeutics vaccines market are engaged in research and development process. For instance, Dendreon Corporation – a biotechnology company engaged in development, discovery and commercialization of novel therapeutic product – launched Provenge, the first FDA-approved immunotherapy drug for treating prostate cancer.

Research and development activities by the major players to favor the therapeutic vaccines market in the near future:

The global therapeutic vaccines market is competitive and highly fragmented. Although, the major players in the market are developing novel products and spending significantly in research and development to give a competitive edge to their peers. For instance, due to the strong product pipeline under therapeutic vaccines segment Merck and GlaxoSmithKline are considered to be the toughest competitor in the market. Key players operating in the therapeutic vaccines market include Novartis AG, GlaxoSmithKline, Pfizer, Cytos Biotechnology AG, Argos Therapeutic Inc., Merck & Co., Dendreon Corp, Bavarian Nordic A/S, and Agenus, Inc.

Key Developments

Key players in the market are focused on R&D of therapeutic vaccines to expand their market share. For instance, in September 2018, Morphogenesis, Inc., a U.S.-based immunotherapy company and Karolinska Institutet (KI) announced the commencement of a two and a half year collaboration combining Morphogenesis’ gene therapy with the exosome-mediated delivery technology developed by the KI Department of Medicine. This is expected to help to develop patient-specific vaccines for the treatment of several types of cancer.

Moreover, Morphogenesis, Inc. is conducting human trials for its cancer vaccine, ImmuneFX for the treatment of severe cutaneous melanoma. The study is expected to be completed in November 2019.

Similarly, in April 2018, Pfizer Inc. received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its TRUMENBA (Meningococcal Group B Vaccine) for active immunization to prevent invasive disease caused by Neisseria meningitidis group B (MenB) in children ages 1 through 9 years.